Such observations have spurred efforts to establish non-invasive screens for TMPRSS2-ETS translocations alone or in conjunction with other prostatic biomarkers to improve risk stratification of men diagnosed with PCa [9, 10]. This evidence concerns the gene TMPRSS2 and posterior cortical atrophy.